Capitol Hill Briefs
This article was originally published in The Gray Sheet
Two House bills that seem simple on the surface – one on protecting “good Samaritans” from liability when they use automatic external defibrillators on cardiac arrest victims; one targeting public educational programs for cell-free DNA prenatal screening – sparked debate at a Dec. 9 Energy and Commerce Committee hearing. Also: legislators are attempting to insert device tax repeal provisions into must-pass 2016 agency funding and tax-extender bills.
You may also be interested in...
CMS Deputy Administrator for Innovation and Quality Patrick Conway and FDA Device Center Director Jeffrey Shuren told a House subcommittee that legislators’ efforts to replace FDA’s proposed laboratory-developed test framework would lead to duplicative, time-consuming, expensive regulation, and could only result in ineffective and delayed diagnostics that might harm patients.
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.